Skip to main content

Erasca, Inc 8-K, filed Nov 12, 2026

Erasca, Inc. (ERAS)

8-K 2026-11-12 For: 2026-11-12
View Original
Added on November 12, 2026

About this 8-K

Erasca, Inc filed this 8-K on November 12, 2026.

Erasca reported that ERAS-0015 received FDA Fast Track Designation for metastatic pancreatic adenocarcinoma, while cash, cash equivalents, and marketable securities totaled $948 million as of September 30, 2026. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits